Price movement over the last 24 hours
Alcon AG vs Ecolab Inc. — how do they compare? Alcon AG trades at $66.94 (market cap $32.69B), while Ecolab Inc. trades at $275.02 (market cap $79.67B). The key difference: Ecolab Inc. is far larger — about 2.4× Alcon AG's market cap, and Ecolab Inc. pays the higher dividend (1.03%). Which is the better fit depends on your goals.
| ALC | ECL | |
|---|---|---|
Market Cap | $32.69B | $79.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $308.35 |
52-Week Low | $62.02 | $245.73 |
Enterprise Value | $36.28B | $88.42B |
Dividend Yield | 0.54% | 1.03% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ECL trades at $283.08, down 0.1% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $1.70, meeting expectations, and maintains strong profitability with a net income margin of 12.8%. Recent acquisition of CoolIT for $4.75B enhances its AI cooling portfolio, positioning for long-term growth. Cash flow from operations remains robust at $3.0B in 2025, though net cash flow turned negative due to significant investing activities.
Outlook is positive with 73% analyst buy ratings and a consensus price target of $326.17, implying 15% upside. Risks include rising costs and integration challenges from acquisitions. The stock's high P/E of 38.39 suggests premium valuation, requiring sustained earnings growth to justify current levels.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →